Xbrane Biopharma AB (XBRANE) - Total Liabilities

Latest as of June 2026: Skr103.76 Million SEK ≈ $11.17 Million USD

Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has total liabilities worth Skr103.76 Million SEK (≈ $11.17 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Xbrane Biopharma AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Xbrane Biopharma AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Xbrane Biopharma AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see XBRANE total assets.

Xbrane Biopharma AB Competitors by Total Liabilities

The table below lists competitors of Xbrane Biopharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Hamashbir 365 Holdings Ltd TA:MSBI	Israel	ILA1.33 Billion
Caldwell Partners International Inc TO:CWL	Canada	CA$36.43 Million
Studio Mir Co. Ltd. KQ:408900	Korea	₩3.93 Billion
DAP Corporation KQ:066900	Korea	₩135.71 Billion
Isofol Medical AB ST:ISOFOL	Sweden	Skr21.52 Million
HG Capital Trust PLC LSE:HGT	UK	GBX38.12 Million
Ratio Energies LP TA:RATI-L	Israel	ILA768.11 Million
Investors House HE:INVEST	Finland	€18.01 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Xbrane Biopharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Xbrane Biopharma AB balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.19	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Xbrane Biopharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Xbrane Biopharma AB (2012–2025)

The table below shows the annual total liabilities of Xbrane Biopharma AB from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr110.97 Million ≈ $11.94 Million	-82.49%
2024-12-31	Skr633.89 Million ≈ $68.22 Million	+31.47%
2023-12-31	Skr482.17 Million ≈ $51.89 Million	+81.52%
2022-12-31	Skr265.63 Million ≈ $28.59 Million	+3.48%
2021-12-31	Skr256.69 Million ≈ $27.62 Million	+24.57%
2020-12-31	Skr206.06 Million ≈ $22.17 Million	+33.27%
2019-12-31	Skr154.62 Million ≈ $16.64 Million	-8.95%
2018-12-31	Skr169.81 Million ≈ $18.27 Million	+652.89%
2017-12-31	Skr22.55 Million ≈ $2.43 Million	+108.67%
2016-12-31	Skr10.81 Million ≈ $1.16 Million	-61.15%
2015-12-31	Skr27.82 Million ≈ $2.99 Million	+7020.88%
2014-12-31	Skr390.70K ≈ $42.05K	-22.70%
2013-12-31	Skr505.44K ≈ $54.39K	-11.15%
2012-12-31	Skr568.90K ≈ $61.22K	--

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$22.40 Million

Skr208.11 Million SEK

Market Cap Rank

#24846 Global

#486 in Sweden

Share Price

Skr10.10

Change (1 day)

-0.98%

52-Week Range

Skr0.25 - Skr23.30

All Time High

Skr176.00